^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Uterine Corpus Leiomyosarcoma |
| Drug Class: | PARP inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review
Published date:
02/24/2022
Excerpt:
In preclinical studies and several case series, poly(adenosine diphosphate-ribose)polymerase inhibitors showed antitumor effects on uLMS cell lines with BRCA2 mutations or HRD and in recurrent or persistent cases of uLMS with BRCA2 mutations.
DOI:
10.3390/cancers14051180
